Management of Chronic Back Pain and Muscle Spasms

Indications for Intrathecal Baclofen Therapy

Intrathecal baclofen therapy is indicated for spasticity of neurological origin, such as multiple sclerosis, spinal cord injury, and cerebral palsy, as well as severe spastic hypertonia that does not respond to other interventions, according to guidelines from the American College of Physicians and American Heart Association/American Stroke Association, with a strength of evidence rated as moderate 1, 2
The American College of Physicians and American Academy of Neurology recommend intrathecal baclofen for chronic stroke patients with spasticity resulting in pain, poor skin hygiene, or decreased function, with a strength of evidence rated as moderate 1, 2, 1

The American College of Physicians and American Pain Society guidelines recommend non-pharmacological approaches, including exercise therapy, physical therapy focused on core strengthening, cognitive behavioral therapy for pain management, and intensive interdisciplinary rehabilitation, with a strength of evidence rated as high 3

The American College of Physicians and American Pain Society guidelines recommend optimization of current gabapentin dosing and consideration of tricyclic antidepressants for chronic pain, with a strength of evidence rated as moderate 3
Alternative muscle relaxants with better evidence for back pain are recommended, although the specific options are not specified, with a strength of evidence rated as low 3
The American College of Physicians and American Pain Society guidelines suggest that there is little evidence for the efficacy of baclofen or dantrolene for low back pain, and recommend considering other options such as acupuncture, massage therapy, spinal manipulation, yoga, cognitive-behavioral therapy, or progressive relaxation 3

Intrathecal administration allows for significantly lower doses (only 10% of systemic doses) while achieving better therapeutic effects, with fewer systemic side effects compared to oral administration, as suggested by the European Society for Medical Oncology 4, 5
Regular pump refills are essential to prevent abrupt discontinuation of therapy and potential life-threatening withdrawal, and monitoring for catheter-related complications is necessary 6
Dosage adjustments may be needed based on clinical response, although the guideline society recommendation for this is not specified in the provided text 5
Abrupt cessation of intrathecal baclofen can lead to a potentially life-threatening withdrawal syndrome, and discontinuation of therapy would likely result in increased spasticity and return of severe pain associated with uncontrolled spasticity, as warned by the Mayo Clinic and other references 6, 7, 5